enVVeno Medical Corporation announced the successful completion of the final wave of implants for shorter-term subjects in its six-month pre-clinical GLP study for enVVe. This achievement means all planned implants in the GLP study, encompassing both long-term and short-term subjects, have been successfully completed.
The enVVe delivery system demonstrated consistent performance throughout the study, indicating robust design and functionality. This successful completion is a crucial step in the development pathway for enVVe, a non-surgical, transcatheter-delivered replacement venous valve.
The company maintains its timeline for submitting the Investigational Device Exemption (IDE) application by mid-2025, pending the final results of the GLP study. This progress positions enVVe as a significant future growth driver for enVVeno Medical.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.